Actively Recruiting
Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer
Led by Children's Hospital of Philadelphia · Updated on 2025-11-14
32
Participants Needed
9
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital of Philadelphia
Lead Sponsor
U
United States Department of Defense
Collaborating Sponsor
AI-Summary
What this Trial Is About
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and is the second most common cancer in adolescent females. Researchers are evaluating how targeted drugs that block genetic drivers of DTC affect the uptake of radioactive iodine (RAI) in tumors, as this impact has not been systematically studied before. The study focuses on patients with metastatic DTC in the lungs receiving these targeted therapies. This observational cohort study enrolls patients receiving oncogene-specific targeted therapy either through routine clinical care or separate therapeutic clinical trials. Patients undergo a baseline whole body radioactive iodine scan before starting therapy and then receive approximately 4 weeks of targeted treatment. After therapy, a second whole body scan is done to assess any changes in RAI-avidity of the tumor. Subsequent treatments are decided by the treating physician or based on the other therapeutic trial the patient may be enrolled in. Participants will have scans performed before and about 28 days after starting targeted therapy to evaluate tumor changes. Researchers measure the proportion of patients whose tumors show increased RAI-avidity after therapy over up to 5 years. The study involves data sharing for those on other targeted therapy trials who agree to share their scan results. Safety monitoring excludes certain groups such as pregnant or breastfeeding females and those needing sedation for scans. The study may continue for several years to observe outcomes.
CONDITIONS
Brief Title
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a confirmed diagnosis of differentiated thyroid cancer
- Presence of specific genetic alterations such as NTRK-fusion, RET-fusion, ALK-fusion, BRAF V600 mutation, or BRAF-fusion identified in an approved laboratory
- Lung metastases visible on chest CT with multiple (10 or more) or enlarging pulmonary nodules
- Planned systemic therapy with an oncogene-specific kinase inhibitor from commercial supply or as part of a separate clinical trial
- Patients already enrolled in other targeted therapy trials who undergo whole body thyroid scan about 28 days after starting therapy and agree to data sharing
You will not qualify if you...
- Prior use of oncogene-specific targeted therapy, except enrollment allowed within 4 weeks of starting therapy if a pre-therapy scan is available
- Pregnant or breastfeeding females
- Patients requiring sedation or general anesthesia for whole body scan
- U.S. Military personnel due to institutional review board requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 weeks
Participants undergo a baseline whole body scan to assess RAI-avidity of their tumor before starting targeted therapy.
1 visit (in-person)
Duration - Approximately 4 weeks
Participants who receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic trial are monitored. Approximately 28 days after starting therapy, a whole body scan is performed to determine changes in tumor RAI-avidity.
1 visit (in-person) about 28 days after beginning therapy
Trial Site Locations
Total: 9 locations
1
University of California San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
2
Emory University School of Medicine
Atlanta, Georgia, United States, 30322
Actively Recruiting
3
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
4
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
5
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
Actively Recruiting
6
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
7
Texas Children's Hospital
Houston, Texas, United States, 77030
Actively Recruiting
8
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Actively Recruiting
9
Children's Hospital Westmead
Sydney, New South Wales, Australia
Actively Recruiting
Research Team
M
Meghan T Donnelly
J
James Robinson
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here